Block TNF to boost immune response in melanoma
Part of Cancer, Skin clinical trials.
This study looks at using a drug that blocks TNF to help the immune system “wake up” better when using cancer immunotherapy for melanoma. You may be eligible only if you are already enrolled in two specific related trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently enrolled in the TICIMEL trial (NCT03293784).
- You are currently enrolled in the MELANFα trial (NCT03348891).
- You meet the study’s setup/eligibility rules to join this add-on treatment while in those trials.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes). The cells are taken from a tumor sample, multiplied in a lab, and given back to you to help fight the cancer. It's for people with melanoma that has not responded to standard immunotherapy.
This trial tests a new way to treat advanced melanoma by taking immune cells from your tumor, enhancing them in the lab to fight better, and giving them back to you. It is for people whose melanoma has spread or cannot be removed, and who have already tried standard treatments.
This early study tests whether “immune recall” (training the immune system using specific vaccine-like steps) can improve how well checkpoint drugs work for advanced melanoma. It is designed mainly to see if the approach is feasible and safe, and it may help some people respond better to PD-1 (with or without CTLA-4) treatment.
This trial tests a combination of immunotherapy treatments for advanced melanoma that has not responded to standard therapy. The goal is to use your own immune cells to fight the cancer more effectively.
This trial tests a type of immune cell therapy called cytokine-induced killer cells for people with advanced melanoma that has not responded to other treatments. It aims to see if these cells can help shrink or slow down the cancer.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.